Central Nervous System (CNS) Biomarkers Market- Growth, Future Prospects And Competitive Analysis, 2018-2026

CNS biomarkers are projected to gain maximum demand during the forecast period from 2018 to 2026, primarily due to extensive ongoing development in personalized medicines and the application of biomarkers in diagnosis. The complexity of the central nervous system paves the way for the development of biomarkers to enhance early diagnosis of neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and other neurological conditions. The growth of the CNS biomarker market is attributed to the growing prevalence of neurological conditions, the aging population, and changing lifestyles. As per the Alzheimer's Association, around 5.5 million Americans suffered from Alzheimer's disease in 2017, of which 5.3 million were elderly patients aged 65 and above. As per the Parkinson's Foundation, around 60 thousand Americans are diagnosed with Parkinson's disease each year. Thus, the growing prevalence increases the demand for efficient diagnostic devices to ascertain positive treatment outcomes, further contributing to the overall growth of the CNS biomarkers market. Additionally, ongoing development in personalized medicines is driving the use of biomarkers to develop efficient and target-specific treatments for chronic neurological conditions.

Of the geographies studied, North America accounted for the maximum market share in 2017, chiefly due to the continuous research activities in developing suitable diagnostic devices and treatment options specific to prevalent CNS biomarkers. Support from regulatory bodies in streamlining approval policies further increases the demand for suitable drug development approaches using biomarkers, diagnostic tools for clinical trials, and the development of personalized medicines. Additionally, high disposable income and a developed healthcare infrastructure further catalyze the CNS biomarkers market's growth in North America.However, high diagnostic assay pricing and a lack of reimbursement policies in low and middle-income economies have a negative impact on market growth overall.

The global central nervous system (CNS) biomarkers market is segmented as follows:

By disease condition

  • Alzheimer's Disease
  • Parkinsons Diseases
  • Multiple Sclerosis
  • Amyotrophic lateral sclerosis
  • Huntington's Disease

By Application

  • Drug Discovery and Development
  • Personalized Medicines
  • Disease Risk Assessment
  • Diagnostics

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • U.K.
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • India
    • China
    • Japan
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

Competitive Outlook:

The market for central nervous system (CNS) biomarkers encompasses a competitive pool with the presence of established players maintaining supremacy. Major industrial players are focusing on the development of diagnostic products for growing neurological conditions, namely Alzheimer's and Parkinson's disease. For instance, Alseres Pharmaceuticals, Inc.'s product Altropane, a molecular imaging agent, is being developed for the diagnosis of Parkinson's disease and dementia. Diagenetic ASA is developing two products, namely, MCItect and ADtect, for the detection of Alzheimer's disease. Other key industrial players competing in this market are Acumen Pharmaceuticals Inc., Banyan Biomarkers Inc., EKF Diagnostics Holdings Inc., Myriad RBM, Thermo Fisher Scientific LLC, etc.

This report offers the following:

  • An overview of the global CNS biomarkers market
  • Market trends and extensive analysis are provided for the forecast period from 2018 to 2026, along with historical data for 2016 and considering 2017 as the base year.
  • Market evaluation pertaining to each segment
  • Qualitative information with respect to market drivers, opportunities, and restraints
  • Detailed information on the existing CNS biomarker diagnostic kits and assay manufacturers
  • A complete understanding of the competitive landscape and profiles of key market players

Frequently Asked Questions:

The market for Central Nervous System (CNS) Biomarkers Market is expected to reach US$ XX Mn By 2026.

The Central Nervous System (CNS) Biomarkers Market is expected to see significant CAGR growth over the coming years, at XX%.

The report is forecasted from 2018-2026.

The base year of this report is 2017.

Acumen Pharmaceuticals Inc., Banyan Biomarkers Inc., EKF Diagnostics Holdings Inc., Myriad RBM, Thermo Fisher Scientific LL are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Mar 2018
Category:  Pharmaceuticals
Report ID:   59004
Report Format:   PDF
Pages:   120
Rating:    4.1 (25)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support